Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ.

Am J Transplant. 2005 Mar;5(3):443-53.

2.

Mutational analysis of the CD6 ligand binding domain.

Skonier JE, Bodian DL, Emswiler J, Bowen MA, Aruffo A, Bajorath J.

Protein Eng. 1997 Aug;10(8):943-7.

PMID:
9415444
3.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS.

J Exp Med. 1997 Jul 7;186(1):47-55.

4.

Identification of amino acid residues important for ligand binding to Fas.

Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA.

J Exp Med. 1997 Apr 21;185(8):1487-92.

5.

Mutational analysis of the CD6 binding site in activated leukocyte cell adhesion molecule.

Skonier JE, Bowen MA, Emswiler J, Aruffo A, Bajorath J.

Biochemistry. 1996 Nov 26;35(47):14743-8.

PMID:
8942635
6.

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.

Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS.

J Biol Chem. 1996 Oct 25;271(43):26762-71.

7.

Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM.

Skonier JE, Bowen MA, Emswiler J, Aruffo A, Bajorath J.

Biochemistry. 1996 Sep 24;35(38):12287-91.

PMID:
8823162
8.

In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.

Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM.

Cancer Res. 1995 Jun 1;55(11):2357-65.

9.

New x-ray contrast agents. The chemical, biological, and physical properties of 5-heterocycle substituted 2,4,6-triiodo-1,3-benzenedicarboxamide derivatives.

Ranganathan RS, Arunachalam T, Diamantidis G, Duncan L, Emswiler J, Marinelli E, Neubeck R, Pillai R, Wedeking P, Tweedle MF.

Invest Radiol. 1991 Nov;26 Suppl 1:S156-8; discussion S165-6. No abstract available.

PMID:
1808114

Supplemental Content

Loading ...
Support Center